No Data
No Data
Hong Kong stocks have experienced abnormal movement, with the concept of innovative drugs leading the way. The National Medical Products Administration has accelerated the approval of clinical pharmaceuticals, and many biotech companies have turned losses
Innovative drug concept has the highest increase. As of the time of writing, Akeso (01541) rose 60.42%, to HKD 6.16; Innocare (09926) rose 12.17%, to HKD 63.15; Innocare (09969) rose 6.19%, to HKD 5.83; Kanoa-B (02162) rose 5.56%, to HKD 39.85.
GTJA: Maintains a "shareholding" rating for CanSino Biologics. The first domestically produced IL-4R monoclonal antibody Kangyueda has been approved.
GTJA released a research report, maintaining a 'shareholding' rating for Connoah-B (02162), taking into account the early entry of CM310 into commercialization, and raising the revenue forecast for 2024 by 0.197 billion yuan (originally 0.156 billion yuan), maintaining the revenue forecast for 2025-2026 at 0.526/1.441 billion yuan. CM310 (known as Kangyueda) for the treatment of moderate to severe AD in adults was approved by the CDE for listing on September 12, becoming the first domestically approved IL-4R monoclonal antibody and the second globally approved, filling the gap in the domestic AD biologics field. The main viewpoints of GTJA are as follows:
Abnormal movement hits directly | Stocks of innovative drugs concept are on the rise, the 2024 ESMO conference is about to be held, and institutions suggest seizing the Q3 fundamentals turning point and industry catalysis.
Innovative drug concept stocks have risen, as of press time, Beigene (06160) rose 6.97%, to HKD 124.3; Innocare-B (02162) rose 4.92%, to HKD 37.35; Innocare (09969) rose 4.91%, to HKD 5.55.
Innocare (09969): Approximately 7.9394 million restricted shares will be listed for trading from September 23.
Innocare (09969) announced that approximately 7.9394 million restricted shares will be released on September 23, 2024...
InnoCare Pharma Agrees With US FDA For Phase 3 Clinical Trail of Orelabrutinib for PPMS Patients; Shanghai Shares Up 4%
HK Stocks Movement | Innocare (09969) surged more than 8% as the clinical research of Aprepitant in the USA Phase III was approved.
Innocare (09969) rose over 8% and as of the time of publication, it was up 8.32% at HKD 5.6, with a turnover of HKD 13.0947 million.
No Data
No Data